Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $739.4 million.

  • Viking Therapeutics' Liabilities and Shareholders Equity fell 2116.17% to $739.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 378.31%. This contributed to the annual value of $908.3 million for FY2024, which is 14649.81% up from last year.
  • As of Q3 2025, Viking Therapeutics' Liabilities and Shareholders Equity stood at $739.4 million, which was down 2116.17% from $827.9 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $967.5 million for Q1 2024, and its period low was $150.9 million during Q1 2023.
  • Its 5-year average for Liabilities and Shareholders Equity is $480.7 million, with a median of $368.5 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 2574.51% in 2022, then skyrocketed by 54118.63% in 2024.
  • Over the past 5 years, Viking Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $210.7 million in 2021, then dropped by 20.0% to $168.5 million in 2022, then surged by 118.65% to $368.5 million in 2023, then surged by 146.5% to $908.3 million in 2024, then decreased by 18.6% to $739.4 million in 2025.
  • Its Liabilities and Shareholders Equity was $739.4 million in Q3 2025, compared to $827.9 million in Q2 2025 and $867.0 million in Q1 2025.